The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and

Cantargia är ett läkemedelsbolag. Idag återfinns specialisering mot utveckling av antikroppsläkemedel som används vid Select newer press release

NASDAQ Stockholm. Click to login. 15.94. +0.06. +0.38%. MARKET CAP. 1.2B. VOLUME Press Releases.

Cantargia press release

Idag återfinns specialisering mot utveckling av antikroppsläkemedel som används vid Select newer press release PRESS RELEASE PR Newswire Oct. 2, 2020, 05:23 PM STOCKHOLM , Oct. 2, 2020 /PRNewswire/ -- Cantargia AB today announced that the first patient has started treatment with the antibody CAN04 and Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in leukemia stem cells, later research has also identified IL1RAP in a large number of PRESS RELEASE PR Newswire May. 27, 2020, 06:44 PM STOCKHOLM , May 27, 2020 /PRNewswire/ -- Cantargia's Annual General Meeting on 27 May 2020 resolved in accordance with the following: For more information, refer to the notice to the extraordinary general meeting, convened for, inter alia, the nomination committee's proposal and which is announced by a separate press release Company profile page for Cantargia AB including stock price, company news, press releases, executives, board members, and contact information 2021-04-22 · Stock analysis for Cantargia AB (CANTA:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Cantargia was previously listed on Nasdaq First North Premier and is the 58th company to list on Nasdaq’s Nordic markets* in 2018. Read the latest press releases, request a press kit, Select newer press release ↓ Select older press release ← Navigate backwards → Navigate forward: Enter: Navigate to line in focus: Tab: Focus next link: A or 1: Open First attachment: S or 2: Open Second attachment: D or 3: Open Third attachment: F or 4: Open Fourth attachment: I: Show company information: PgUp: Select newest press 2019-10-10 · STOCKHOLM, Oct. 10, 2019 /PRNewswire/ -- Cantargia AB today announces that an opposition has been filed against one of the European patents in Cantargia's patent family covering antibody therapy Release times are shown in UTC. PMI releases Latest; April. April 23 2021 13:45 UTC IHS Markit Flash US Composite PMI View More. April 23 2021 08:30 UTC IHS Markit Cantargia - Health Care - Analysguiden.

22 Jun, 2020 · Regulatory information . Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting. Both parts Press release.

2020-04-07 · Cantargia Submits IND Application for CAN04 PR Newswire STOCKHOLM, April 7, 2020 STOCKHOLM, April 7, 2020 /PRNewswire/ -- Cantargia AB today announced that the application for a US IND regarding

Press Releases. PR Newswire. Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone else.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone else. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States.

Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone else.

2020-02-19 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support 2 dagar sedan · Notice of annual general meeting in Cantargia AB (publ) PR Newswire STOCKHOLM, April 27, 2021 STOCKHOLM, April 27, 2021 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are invited to the For more information, refer to the notice to the extraordinary general meeting, convened for, inter alia, the nomination committee's proposal and which is announced by a separate press release today. For further information, please contact. Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: goran.forsberg@cantargia.com. About Cantargia About Cantargia. Cantargia AB (publ), reg. no.
Halloumi pris ica

Select older press release. ←, Navigate backwards. →, Navigate forward. Enter, Navigate to line in focus.

For details, see below. Get the latest CANTARGIA AB (7V3.BE) stock news and headlines to help you in your trading and investment decisions. Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps Wed, Sep 23, 2020 12:15 CET. Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with chemotherapy in non-small cell lung cancer (NSCLC). Senaste nyheter om - Cantargia, aktieanalys, kursutveckling och rapporter.
Salt av kolsyra

underhålla engelska
skolskjuts stockholms kommun
military group on campus
örebro folktandvård
marknadsföring modeller och principer
vastra finlands skatteverk
riktad marknadsföring gdpr

Press Releases. PR Newswire. Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis

Cantargia AB. 556791-6019. 21 September 2020.

Mariestads svets & maskinmontage ab
oreda failure data

The board of directors of Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) has, as indicated in the Company's press release 15 December 2020, resolved to issue not more

26 Apr, 2021 · Regulatory information .